ClinicalTrials.gg
RecruitingNCT05565222PITAGOREUpdated Apr 18, 2023

Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit

A Phase 3 interventional study of Piperacillin/tazobactam or temocillin and Meropenem in Sepsis and Septic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris — 15 open to participants now, 16 under way, 3 of them phase 3. Shock, Septic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 17
600 · median 210
Started
2023
with 1 other
Phase 3
8 of 30
3 open now
Primary completion
2026-04
later than 7 of 15 live
Registered
19th of 30
by date

Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 in phase 3, reaches primary completion later than 7 of the 15 other live ones, and was the 19th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

15 of the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a major public health concern, in particular in the intensive care unit (ICU), due to the increase in their incidence. Carbapenems are the treatment of choice of these infections, but their increased use may select for carbapenem resistance in Gram-negative bacilli, which currently represents the greatest threat in terms of antibiotic resistance. Several retrospective studies have shown that the use of non-carbapenem antibiotics (mainly the association of piperacillin/tazobactam, but also cefepime and temocillin) may be safe alternatives to carbapenems to treat these pathogens when the strain is susceptible to the corresponding antibiotic. However, one recent randomized controlled study, the Merino trial, failed to demonstrate the non-inferiority of piperacillin/tazobactam, as compared to meropenem, in patients with Gram-negative bacilli bacteremia resistant to third generation cephalosporins (mainly ESBL producers). However, the patients included in that study were not ICU patients, dosing and modalities of piperacillin/tazobactam administration were not optimal (30-min infusion whereas 4-hours infusion may be associated with better outcome), and cause of death of patients in the piperacillin/tazobactam arm were not due to antimicrobial treatment failure (mostly death due to care withdrawal in cancer patients). Recently, a retrospective bicenter study performed in ICU patients showed that outcome of patients with severe infection (i.e. sepsis and septic shock according to the Sepsis-3 definition) due to ESBL-producing Enterobacteriaceae susceptible to non-carbapenem agents treated with a non-carbapenem agent was similar to that of patients treated with carbapenems.

Given the scarcity of data in ICU patients, the disputable results of the Merino trial, we will therefore conduct a multicenter, randomized, open-label trial of non-carbapenem beta-lactam (piperacillin/tazobactam or temocillin) treatment vs. meropenem treatment for ESBL-producing Enterobaceriaceae severe infection in ICU patients. Our hypothesis is that a non-carbapenem beta-lactam treatment is non-inferior to carbapenem treatment in patients with ESBL-producing Enterobacteriaceae severe infection in the ICU.

03

Conditions studied

  • Sepsis
  • Septic Shock

Browse trials for

Keywords

  • carbapenem-alternatives
  • severe infections
04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 600 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18-year-old
  • Hospitalized in the ICU
  • Severe infection, eg sepsis or septic shock (according to the Sepsis-3 definition) Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, characterized by an increase of Sequential Organ Failure Assessment (SOFA) score of 2 points or more. This increase in 2 points will be calculated the day infection is diagnosed (day of positive culture serving as reference for the infection) as compared to the day before infection onset.

Septic shock is defined as sepsis and persisting hypotension requiring vasopressors to maintain mean arterial pressure ≥65 mmHg and having a serum lactate level >2 mmol/l despite adequate volume resuscitation.

This criterion (sepsis or septic shock) has to be fulfilled within a time frame of +/- 24 hours from the day of infection diagnosis (i.e. the day of positive bacteriological sample).

  • Pathogen responsible for infection is an ESBL-producing Enterobacteriaceae susceptible to meropenem and either to piperacillin/tazobactam (minimum inhibitory concentration \<8 mg/L) or to temocillin (minimum inhibitory concentration ≤8 mg/L)
  • Signed from patient/a legal representative/a family member/a close relative. According to the specifications of emergency inclusion, randomization without the close relative or surrogate consent could be performed if the patient is unable to give his/her consent and when the legal representative/family member or close relative are absent except patients included in another study for which emergency inclusion has already been used (see exclusion criteria n° 8). For these patients, emergency inclusion cannot be used). Close relative/surrogate/family consent will be asked as soon as possible. The patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow
  • Affiliation to social security (AME excluded)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Known allergy to beta-lactam
  • Patient with severe neutropenia, as defined by \<0.5x109/L
  • Infection requiring prolonged antimicrobial treatment (endocarditis; mediastinitis; osteomyelitis/septic arthritis; undrainable/undrained abscess; unremovable/unremoved prosthetic-associated infection)
  • Moribund, defined by a SAPS II score at inclusion >75
  • Decision of withholding/withdrawing care
  • Patient with concomitant infection requiring antibiotics with activity against Gram-negative bacilli, including patient with polymicrobial infection with pathogen resistant to study drugs
  • Participation in another interventional study evaluating drugs or being in the exclusion period at the end of a previous study evaluating drugs .
  • to any components of the formulations
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Piperacillin/tazobactam or temocillin

    Piperacillin/tazobactam, 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure). Piperacillin/tazobactam will be infused over 4 hours. Duration of treatment will be adjusted according to the site of infection Temocillin, 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure). Temocillin will be infused continuously. Duration of treatment will be adjusted according to the site of infection

    Drug: Piperacillin/tazobactam or temocillin

  • Active comparator
    Meropenem

    2 g every 8 hours by intravenous route (adjusted in case of renal failure). Meropenem will be infused over 2 hours. Duration of treatment will be adjusted according to the site of infection

    Drug: Meropenem

Interventions

  • DrugPiperacillin/tazobactam or temocillin

    Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure). Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)

  • 2 g every 8 hours by intravenous route (adjusted in case of renal failure)

07

What researchers measure

Primary outcomes

  1. Mortality

    Time frame: Day 30

Secondary outcomes

  1. Mortality

    Time frame: Day 90

  2. Relapses rates of extended-spectrum beta-lactamase infection

    Time frame: Day 30

  3. Clinical failure rate

    relapse of ESBL infection or death

    Time frame: Day 30

  4. Rate of antibiotic allergy

    Time frame: Day 30

  5. Incidence of adverse drug reactions

    Time frame: Between randomization and Day 90

  6. Duration of hospitalization stay

    Time frame: Between randomization and Day 90

  7. Duration of ICU stay

    Time frame: Between randomization and Day 90

  8. Number of days alive without antibiotics

    Time frame: Between randomization and Day 30

  9. Days with organ failure asessed by sequential organ failure assessment

    Time frame: Between randomization and Day 30

  10. Rate of faecal colonization with carbapenem-resistant Gram-negative bacilli

    Time frame: End of treatment, ICU discharge and day 90

  11. Rate of Clostridium difficile infection

    Time frame: Day 90

  12. Rate of secondary nosocomial infection

    Time frame: Day 90

  13. Proportion of patients in whom duration of antimicrobial treatment of the index episode has been exceeded compared to the recommended duration

    Time frame: Through completion of study treatment, an average of 10 days and up to 21 days

  14. Proportion of patients who change their treatment before the recommended duration without relapse

    = cross-over

    Time frame: Through completion of study treatment, an average of 10 days and up to 21 days

08

Study locations

2 of 2 sites recruiting
  • LUYT Charles -Edouard
    Paris, 75013, France
    Recruiting
  • MAYAUX Julien
    Paris, 75013, France
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Apr 2026, 37 months after the start.

Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 37 months is below that.

Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Oct 4, 2022
StartActual
Mar 11, 2023
Primary completionEst.
Apr 2026
CompletionEst.
Jun 2026
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05565222
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Mar 11, 2023
Primary completion
Apr 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion